1. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union;Moulard;Eur J Haematol,2014
2. MIPSS70+ Version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis;Tefferi;J Clin Oncol,2018
3. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis;Harrison;Leukemia,2016
4. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis;Mesa;J Clin Oncol,2017
5. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial;Harrison;Lancet,2018